introduction
Radical prostatectomy (RP) is commonly accepted as a treatment with excellent oncologic results in cancer confined to the prostate. 1, 2 However, positive surgical margins (PSM), as well pT3 lesion and extra-capsular extension, have been recognized as predictors of biochemical and local recurrence. 3, 4 Three randomized clinical trials have addressed the role of adjuvant radiotherapy (AR) following RP for highrisk prostate cancer (PC). 5, 7 These trials showed biochemical and local relapse-free survival advantages, but failed to demonstrate long-term metastasis-free and overall survival superiority. Thompson et al. 8 published a long-term follow-up of their previous randomized trial. This is the only known report suggesting that AR provides superior metastasis-free survival and overall survival. This study reports a retrospective analysis of the author's experience in the adjuvant treatment of resected high-risk prostate cancer. The initial assumption is that AR can offer better oncologic outcomes compared to observation alone (OA).
Methods
After the approval of the Local Research Ethics Committee, all medical records of patients who underwent radical prostatectomy for prostate cancer between January 1995 and December 2005 at our Department were evaluated. Patients with 2010-AJCC (American Joint Commitee on Cancer) pT3 stage, with or without positive surgical margins at definitive pathologic analysis, were selected for possible analysis. Patients that received neo- Table 2 demonstrates the final pathology report of the specimen. Pathologic clinical stage and extra-capsular invasion were similar. PSM were more common in the AR group (89.7%) than in the OA group (50%) -p=0.0116. Follow-up outcomes included the indication of adjuvant radiotherapy or observation alone, presence of biochemical recurrence (considered as 0.2 ng/dL PSA level above nadir), diagnosis of bone metastasis (indicated by bone radiography, computed tomography or bone scan), need for rescue androgen deprivation therapy and rescue radiotherapy, and follow-up length.
Death was considered related to prostate cancer if secondary to local complications (pelvic) or metastatic disease.
Patients were divided into 2 groups for comparison purposes: the adjuvant radiotherapy group, and the observation alone group.
Primary end-point analysis was biochemical progression-free survival. Secondary end-points were need for rescue androgen deprivation therapy, metastasis-free survival and overall survival.
Statistical analysis was carried out using SPSS v.17, EPI info 3.5 software, applying Chi-Square, Fisher's exact test and Student's t-test, when necessary. Biochemical relapsefree survival was calculated using Kaplan-Meier method with log-rank test. The p-values were two sided at the significance level of <0.05.
results

Demographics
From January 1995 to December 2005, 739 patients were treated for PC at Erasto Gaertner Hospital with RP. Forty-nine presented with pT3 with or without PSM at definitive pathologic analysis.
After verifying that no exclusion criteria could be applied, those 49 patients were included for analysis. Thirty-nine (79.6%) received AR, and 10 (20.4%) were observed without initial intervention. Table 1 shows baseline demographic characteristics. Mean age at diagnosis, ASA score, preoperative PSA and Gleason score at biopsy were similar among groups.
• Bone metastasis occurred in only one patient in each group (p=0.37). No cancer-specific death occurred during the follow-up period. 
discussion
These results show a significant longer biochemical relapse-free survival and a significant lower need of rescue ADT, in patients treated with AR for high-risk resected PC. Bone metastasis was a rare event, and the authors did not register mortality directly related to PC.
Limitations of this analysis include its retrospective nature and heterogeneity in some characteristics between groups.
Similar results have been reported by several retrospective, non-randomized studies, 9,10 all sharing similar bias common to such retrospective analyses.
In 2005, the European Organisation for Research and Treatment of Cancer (EORTC) trial 22911 5 was the first large, multicentric, randomized trial, trying to evaluate the role of AR in high-risk resected PC. This study found better biochemical relapse and clinical local relapse-free survival, but could not assess metastasis-free survival and overall survival due to the short follow-up.
Thompson et al. 6 published the second large randomized trial assessing the same question. This study had a more audacious primary end-point, metastasis-free survival. It failed in reaching this end-point, with a tendency to better distant failure outcomes with AR, but without reaching statistical significance (p=0.06). Overall survival advantage could not be proved, at a mean followup of 10.9 years (p=0.16). Similar to EORTC 22911 results, AR showed significant better biochemical relapse and local relapse-free survival.
In 2009, Thompson et al. 8 published a longer followup of their previous reported trial. With a median followup of 12.7 years, they could demonstrate a significant better metastasis-free survival (HR 0.71 in favor of AR) and a significant better overall survival (15.2 versus 13.3 years, HR 0.72 in favor of AR). To date, this is the only report of metastasis-free and overall survival advantage of AR.
The ARO96-02/AUO AP09/95 trial, 7 published in 2009, the last randomized trial published comparing AR A common criticism to these randomized studies is the small radiation dose, generally from 60 to 64 Gy, and a high proportion of patients treated with 2D technique. Such protocol was the standard radiotherapy treatment when many of the included patients were randomized. Today, common treatment is 66 to 80 Gy, delivered with 3D or intensity-modulated radiation therapy (IMRT) planning. 9, 11 However, this bias should probably not influence negatively data interpretation. Some suggest that the clinical results of these trials are underestimated by the worse radiotherapy technique available at the time, and that new trials with modern protocols could probably lead to even better results.
Differently from 2005, when the last patients selected for this analysis were included, AR is now a well-accepted therapy, and is offered routinely to our patients when presenting with a high-risk resected PC.
During the evaluated period, 1995-2005, AR was not a standard protocol at Erasto Gaertner Hospital. At the time, we did not have the results of the previous described trials. [5] [6] [7] [8] We could not identify selection criteria to AR or OA adopted in the patients, other than personal preference of the attending oncologist. This can generate a selection bias, not uncommon in such retrospective studies.
Nevertheless, we emphasize that if the two analyzed groups were different, AR group can be considered a higher risk group, due to the significant higher proportion of PSM. Even with predictable worse outcomes in this group, AR could actually overcome the worst prognosis, and show a significant longer biochemical relapse-free survival.
Another important result is the significant less dependency of rescue ADT in AR group. ADT use is a frequent worry for the oncologist, due to the expiration date of its benefits and the known short and long-term side effects.
conclusion
In agreement to growing and already strong evidence in favor to AR after resected high-risk PC, the authors showed significant better outcomes with adjuvant radiotherapy.
Although proving better metastasis-free and overall survival advantages in PC is difficult, it was already suggested in previous randomized trials that the biochemical advantage of AR also translates into better clinical outcomes.
In the author's opinion, AR provided better treatment in these selected patients, it is now the first choice when facing high-risk resected PC, and should always be offered as an option to the patient. Resultados: entre os 739 pacientes tratados com prostatectomia radical, 49 apresentaram tumores pT3, com ou sem margens cirúrgicas positivas. Trinta e nove receberam RA e 10 foram submetidos à vigilância. O seguimento médio foi de 6,2 anos para a RA e de 7,3 anos para a vigilância. Houve progressão bioquímica em 12,8% dos pacientes no grupo RA e em 70%, no grupo da vigilância (p=0,0008). A sobrevida livre de progressão bioquímica em 5 anos foi de 87,1% na RA e 30% na vigilância (HR 0,12, IC95% 0,03-0,48 -p<0,0001). Terapia hormonal de resgate foi necessária em 2,6% dos pacientes na RA e em 30% na vigilância (p=0,023). Conclusões: a radioterapia adjuvante após prostatectomia radical em pacientes com câncer de próstata de alto risco ofereceu melhores resultados bioquímicos. Ainda não está claro se isso se traduz em uma evolução clínica melhor.
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